🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

505 results for “Oral” Clear

  1. Oral Treprostinil

    United Therapeutics Europe Ltd

    Pulmonary Hypertension Associated With Sickle Cell Disease

    phase 3 small molecule terminated

    1 trial

  2. Oral dexamethasone

    Hospital Authority, Hong Kong

    Bronchiolitis

    phase 3 small molecule completed

    1 trial

  3. Oral immunonutrition

    Hospital Authority, Hong Kong

    Non Small Cell Lung Cancer

    phase 3 other active

    1 trial

  4. Oral micronized progesterone

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 3 small molecule completed

    1 trial

  5. Oral semaglutide

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  6. Oral sulfate solution (OSS)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Bowel Preparation for Colonoscopy

    phase 3 small molecule completed

    1 trial

  7. Oral treprostinil

    United Therapeutics Europe Ltd

    Pulmonary Hypertension

    phase 3 small molecule terminated

    2 trials

  8. Oral treprostinil (UT-15C) sustained release tablets

    United Therapeutics Europe Ltd

    Pulmonary Hypertension

    phase 3 small molecule completed

    2 trials

  9. Oral triiodothyronine

    Cardiff Oncology

    Postoperative; Dysfunction Following Cardiac Surgery

    phase 3 small molecule completed

    1 trial

  10. PL1 - Placebo to match losmapimod tablets are tablets for oral administration and visually match the active losmapimod tablets, 15 mg., Losmapimod

    Fulcrum Therapeutics

    Facioscapulohumeral Muscular Dystrophy (FSHD)

    phase 3 small molecule active

    1 trial

  11. PLACEBO OF VANCOMYCINE = NaCl 0.9% ( oral use ), Vancomycine Viatris 500 mg poudre pour solution pour perfusion

    Pari Pharma GmbH

    Patients hospitalized for allogeneic hematopoietic stem cell transplantation

    phase 3 small molecule active

    1 trial

  12. PLACEBO for GIVINOSTAT hydrochloride monohydrate (ITF2357) 10 mg/mL oral suspension, ITF2357

    Italfarmaco S.p.A.

    Duchenne muscular dystrophy (DMD)

    phase 3 small molecule active

    1 trial

  13. PLACEBO, Nicetile 500 mg polvere per soluzione orale

    Istituto Gentili S.r.l.

    amyotrophic lateral sclerosis

    phase 3 small molecule active

    1 trial

  14. PROTAMINE CHOAY 1000 U.A.H./ml, solution injectable

    Pari Pharma GmbH

    Any patients ≥18 years old, eligible for transfemoral TAVI with coverage for medical insurance

    phase 3 small molecule active

    1 trial

  15. Peanut food challenge, oral paste “high dose” - 133.3 mg/g peanut proteins, Peanut food challenge, oral paste “placebo” - Placebo formulation, Soluprick Positive control, 10 mg/ml, Solution for skin-prick test, Viaskin Peanut, Soluprick Negative control, Solution for skin prick test, ALK 762 Jordnød, Opløsning til priktest (Soluprick), Nøddeallergen, The DBV712 Placebo Patch is the same system as DBV712 250 mcg Patch but without peanut proteins, Peanut food challenge, oral paste “low dose” - 6.6 mg/g peanut

    DBV Technologies

    Peanut allergy

    phase 3 small molecule active

    1 trial

  16. Peanut food challenge, oral paste “placebo” - Placebo formulation, Viaskin Peanut, Peanut food challenge, oral paste “low dose” - 6.6 mg/g peanut proteins, Peanut food challenge, oral paste “high dose” - 133.3 mg/g peanut proteins

    DBV Technologies

    Peanut allergy

    phase 3 small molecule active

    1 trial

  17. Placebo - Film coated tablet for oral use, atrasentan

    Novartis Pharmaceuticals

    Immunoglobulin A Nephropathy (IgAN)

    phase 3 small molecule active

    1 trial

  18. Placebo - Staloral birch, oromucosal solution, STALORAL Birke 10 IR/ml und 300 IR/ml, Lösung zur Anwendung in der Mundhöhle, STALORAL Birke 300 IR/ml, Lösung zur Anwendung in der Mundhöhle

    Allergen

    Birch Pollen-induced Allergic Rhinoconjunctivitis

    phase 3 small molecule active

    1 trial

  19. Placebo double encapsulated oral transplant of fecal microbiota, Double encapsulated oral transplant of fecal microbiota

    Pari Pharma GmbH

    Adults Non Diabete Remission (NDR) Type 2 Diabete (T2D) patients 1 to 5 years after bariatric surgery

    phase 3 small molecule active

    1 trial

  20. Placebo double encapsulated oral transplant of fecal microbiota, Double encapsulated oral transplant of fecal microbiota

    Pari Pharma GmbH

    Patients colonized with MDR-GNB

    phase 3 small molecule active

    1 trial

  21. Placebo of Procoralan 5 mg, Procoralan 5 mg film-coated tablets

    Pari Pharma GmbH

    Septic shock

    phase 3 small molecule active

    1 trial

  22. Placebo tablets to match S95032 drug product are supplied as film-coated tablets for oral administration., S95032/AG-881, S95032/AG-881

    Ningbo Cancer Hospital

    ​​IDH-mutant grade 2 or 3 astrocytoma​

    phase 3 small molecule active

    1 trial

  23. Placebo tablets to match S95032 drug product are supplied as white to off-white, round (10 mg) and white to off-white oblong (40 mg) film-coated tablets for oral administration., S95032/AG-881, S95032/AG-881

    The George Institute

    Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation

    phase 3 small molecule active

    1 trial

  24. Placebo to Mexiletine granules for prolonged-release oral suspension 167 mg, 333 mg, and 500 mg, Mexiletine granules for prolonged-release oral suspension 333 mg, Mexiletine granules for prolonged-release oral suspension 500 mg, Mexiletine granules for prolonged-release oral suspension 167 mg

    Lupin Europe GmbH

    Myotonic Dystrophy type 1 and type 2 (DM1/DM2)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources